PL439809A1 - Metody wytwarzania przeciwciała anty-alfa4beta7 - Google Patents

Metody wytwarzania przeciwciała anty-alfa4beta7

Info

Publication number
PL439809A1
PL439809A1 PL439809A PL43980920A PL439809A1 PL 439809 A1 PL439809 A1 PL 439809A1 PL 439809 A PL439809 A PL 439809A PL 43980920 A PL43980920 A PL 43980920A PL 439809 A1 PL439809 A1 PL 439809A1
Authority
PL
Poland
Prior art keywords
antibody
methods
vedolizumab
making anti
integrin antibody
Prior art date
Application number
PL439809A
Other languages
English (en)
Inventor
Debra AMELI
Susan R. CARTER
Michael E. DOLAN
Nicole HILO
Amitava Kundu
Amy MILLER
George PARKS
Olga PALEY
Paras BHATIA
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of PL439809A1 publication Critical patent/PL439809A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Przedmiotem zgłoszenia są metody oczyszczania przeciwciała anty-α4β7 przeciwko integrynie, takiego jak wedolizumab, z roztworu płynnego, np. z klarownego zbioru hodowli komórek ssaków. Wynalazek dotyczy m.in. metod oczyszczania w celu kontrolowania ilości substancji związanych z produktem i/lub zanieczyszczeń procesowych obecnych w związanych z oczyszczonych preparatów przeciwciała anty-α4β7 przeciwko integrynie lub jego fragmentu wiążącego antygen, na przykład wedolizumabu. Zgłoszenie obejmuje też kompozycje zawierające przeciwciało anty-α4β7 i ich zastosowania do leczenia zaburzenia.
PL439809A 2019-06-10 2020-06-10 Metody wytwarzania przeciwciała anty-alfa4beta7 PL439809A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962859494P 2019-06-10 2019-06-10
PCT/US2020/037059 WO2020252069A1 (en) 2019-06-10 2020-06-10 METHODS OF PRODUCING AN ANTI-α4β7 ANTIBODY

Publications (1)

Publication Number Publication Date
PL439809A1 true PL439809A1 (pl) 2022-12-05

Family

ID=73781728

Family Applications (1)

Application Number Title Priority Date Filing Date
PL439809A PL439809A1 (pl) 2019-06-10 2020-06-10 Metody wytwarzania przeciwciała anty-alfa4beta7

Country Status (14)

Country Link
US (1) US20220267449A1 (pl)
EP (1) EP3980466A4 (pl)
JP (2) JP7624414B2 (pl)
CN (2) CN114375307B (pl)
AR (1) AR119270A1 (pl)
AU (1) AU2020290943A1 (pl)
BR (1) BR112021024897A2 (pl)
CA (1) CA3143167A1 (pl)
IL (1) IL288825A (pl)
MA (1) MA56129A (pl)
MX (1) MX2021015300A (pl)
PL (1) PL439809A1 (pl)
TW (1) TW202112818A (pl)
WO (1) WO2020252069A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019198099A1 (en) * 2018-04-10 2019-10-17 Dr. Reddy's Laboratories Limited Stable antibody formulation
EP3773696A4 (en) 2018-04-10 2021-12-29 Dr. Reddy's Laboratories Ltd. Stable formulations of therapeutic antibody
WO2023007516A1 (en) * 2021-07-29 2023-02-02 Dr. Reddy’S Laboratories Limited Method to control high molecular weight aggregates in an antibody composition
WO2023012828A1 (en) * 2021-08-05 2023-02-09 Dr. Reddy's Laboratories Limited Method to purify an antibody composition using cation exchange chromatography
WO2023031965A1 (en) * 2021-09-03 2023-03-09 Dr. Reddy’S Laboratories Limited Method to obtain a purified antibody composition
WO2024233992A2 (en) * 2023-05-11 2024-11-14 Trophogen, Inc. Methods of manufacturing highly glycosylated glycoprotein hormones and their analogs
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2014142882A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
JP6293907B2 (ja) * 2014-03-10 2018-03-14 リヒター ゲデオン エヌワイアールティー． プレクリーニング工程を用いた免疫グロブリンの精製
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive

Also Published As

Publication number Publication date
IL288825A (en) 2022-02-01
JP7624414B2 (ja) 2025-01-30
MA56129A (fr) 2022-04-13
CN114375307B (zh) 2025-12-05
JP2025063035A (ja) 2025-04-15
US20220267449A1 (en) 2022-08-25
EP3980466A4 (en) 2023-06-07
CN119859188A (zh) 2025-04-22
AU2020290943A1 (en) 2022-02-03
WO2020252069A1 (en) 2020-12-17
MX2021015300A (es) 2022-02-03
BR112021024897A2 (pt) 2022-01-18
TW202112818A (zh) 2021-04-01
JP2022536486A (ja) 2022-08-17
CN114375307A (zh) 2022-04-19
EP3980466A1 (en) 2022-04-13
AR119270A1 (es) 2021-12-09
CA3143167A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
PL439809A1 (pl) Metody wytwarzania przeciwciała anty-alfa4beta7
RU2768003C2 (ru) Интегрированное непрерывное производство терапевтических белковых лекарственных веществ
AR122348A2 (es) Métodos y composiciones para tolerancia a herbicidas en plantas
Levi et al. CD105 protein depletion enhances human adipose-derived stromal cell osteogenesis through reduction of transforming growth factor β1 (TGF-β1) signaling
PH12020500549A1 (en) Methods and compositions for ppo herbicide tolerance
BR112017023912A2 (pt) sistema modular e processo para produção contínua e/ou processamento de um produto de forma desinfectada
PH12020500027A1 (en) Purification of iduronate-2-sulfatase
RU2014138499A (ru) АНТИГЕНСВЯЗЫВАЮЩАЯ МОЛЕКУЛА ДЛЯ УСКОРЕНИЯ ИСЧЕЗНОВЕНИЯ АНТИГЕНА ЧЕРЕЗ FycRIIB
BR112021024848A2 (pt) Métodos de purificação de anticorpos e composições dos mesmos
FI20185493L (fi) Menetelmä ja laitteisto biologista alkuperää olevan materiaalin puhdistamiseksi
BR112015009553A2 (pt) Método para separar uma proteína de interesse de uma solução de cultura de células
EA202092088A1 (ru) Антитела анти-phf-тау и их применение
MX372711B (es) Metodos para la purificacion de arilsulfatasa a.
UA115235C2 (uk) Ген токсину axmi335 bacillus thuringiensis та спосіб його застосування
PE20231747A1 (es) Acido nucleico que codifica una entidad anti-vegf y un regulador del complemento negativo y sus usos para el tratamiento de la degeneracion macular relacionada con la edad
FI3063287T3 (fi) Monensiinin käyttö rekombinanttiproteiinien glykosylaation säätelyyn
PH12021552001A1 (en) Producing compositions comprising two or more antibodies
MX2017008633A (es) Procedimiento para preparar una proteina de fusion tnfr-fc que contiene un contenido objetivo de impurezas.
Poulsen et al. Mammalian perfusion cultivation at high L-Arginine concentration for efficient production of recombinant protein by increasing perfusion filter transmission
TR2023014436T (tr) Afi̇ni̇te kromatografi̇si̇ i̇le protei̇n saflaştirilmasi
TH143483A (th) การทำให้ตัวยับยั้งเอนไซม์แอลฟ่า1-โปรตีเอสที่ได้จากเซลล์เพาะเลี้ยงบริสุทธิ์
Allalasandra et al. Hypoxia Primed Placental Mesenchymal Stem Cells For Wound Healing
BR112023020433A2 (pt) Método para purificar proteínas, intermediário farmacêutico, proteína purificada, proteína cristalizada, preparação farmacêutica, proteína, método de tratamento, proteína para uso e unidade de dosagem
Amid Effects of Extraction, Purification and Freeze Drying Conditions on Enzymatic Properties of Serine Protease from Mango (Mangifera Indica L. Cv. Chokanan) Peel
Roudkenar Human Plasma Derived Drugs Separation by Fractionation of Plasmawith Polyethylene Glycol